Netherlands · Biotechnology startup
Netherlands · ProQR Therapeutics
Changing lives is what drives us at ProQR Therapeutics.
Funding reportedLast round: Post-IPO Equity
About ProQR Therapeutics
Changing lives is what drives us at ProQR Therapeutics.
We are advancing our proprietary AxiomerTM RNA-editing platform technology. Our highly energetic team strives to combine innovative technologies and entrepreneurism to make a meaningful impact on the lives of individuals and the people around them. If you are up to this challenge and like to be part of our team, check out our website for vacancies: http://www.proqr.com/careers/
What company datasets say ProQR Therapeutics raised
Funding, as reported
Founders and team
From ProQR Therapeutics's own website: 6 on the team.
- Bart FiliusNon-Executive Director
- Begoña Carreño PhDNon-Executive Director
- Daniel A. de BoerExecutive Director
- Gerard PlatenburgExecutive Director
- Sarah KielyBoard of Directors
- Theresa HeggieNon-Executive Director
AdvisersThomas Wolf
On a portfolio page
Investors who name them
Each firm lists ProQR Therapeutics on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
Biotechnology in Netherlands
Startups like it
Is this your company?
Add your raise, your deck and your story, and put ProQR Therapeutics in front of investors. Or tell us what we have wrong.